AAIC 2025 Abstract
ABIDEing with automated cerebrospinal fluid assays; update of an MCI to dementia prediction model
By Pieter J. van der Veere, Argonde C. van Harten, Ingrid S. van Maurik, Show 34 more authorsWiesje M. van der Flier
Study in peopleBiomarkers
Abstract
Background: Automated cerebrospinal fluid (CSF) biomarker assays have largely replaced manual immunoassays for measuring amyloid pathology. Their relevance is increasing as amyloid‐targeting therapies (ATTs) are becoming available for amyloid‐positive mild cognitively impaired (MCI) individuals.
